The Angiotensin-(1-7) Axis: Formation and Metabolism Pathways
- 118 Downloads
The renin-angiotensin system (RAS) constitutes a key hormonal system in the physiological regulation of blood pressure via peripheral and central mechanisms. Dysregulation of the RAS is considered a major factor in the development of cardiovascular pathologies and pharmacologic blockade of this system by the inhibition of angiotensin-converting enzyme (ACE) or antagonism of the angiotensin type 1 receptor (AT1R) is an effective therapeutic regimen. The RAS is now defined as a more complex system composed of different angiotensin peptides with diverse biological actions mediated by distinct receptor subtypes. The classic RAS comprises the ACE-Ang II-AT1R axis that promotes vasoconstriction, water intake, sodium retention and increased oxidative stress, fibrosis, cellular growth, and inflammation. The non-classical or alternative RAS is composed primarily of the ACE2-Ang-(1-7)-AT7R pathway that opposes many actions of the Ang II-AT1R axis. In lieu of the complexity of this system, the chapter discusses the current evidence on the enzymatic cascade of the Ang-(1-7) axis of the RAS regarding the peptidases that contribute to the formation and degradation of the peptide in the circulation and various tissues.
KeywordsAngiotensin-(1-7) Neprilysin Dipeptidyl peptidase 3 ACE ACE2 Renin Thimet oligopeptidase Prolyl carboxypeptidase Prolyl oligopeptidase
Angiotensin-(1-7) Forming Pathways
Renin [EC 18.104.22.168, 35 kDa] belongs to the class of aspartyl-type acid proteases but exhibits a more neutral pH optima [6.5–8.0] than other proteases in this group. The only known substrate for renin is angiotensinogen and the enzyme hydrolyzes the Leu10-Leu11/Val11 bond of the precursor protein to form the inactive peptide Ang I. Renin-dependent formation of Ang I is considered the enzymatic initiator of the RAS cascade to ultimately generate Ang II (Fig. 1). The enzyme is synthesized predominantly in the juxtaglomerular (JG) cells of the kidney and is stored in both inactive (pro-renin) and active forms for the regulated release of the protease into the circulation. The collecting duct (CD) cells are another source of renin within the kidney that primarily secretes the active form of renin into the tubular fluid [12, 13, 14]. The tubular secretion of renin may contribute to the processing of angiotensinogen and subsequent Ang II and Ang-(1-7) formation to influence distal nephron function. The regulation of JG renin appears to be quite distinct from CD renin; Ang II negatively regulates JG renin release through inhibition of cAMP levels that constitutes the short negative feedback loop while CD renin release is stimulated by Ang II that may reflect increased protein kinase C (PKC) activity .
In regard to the generation of Ang-(1-7), renin is required for the formation of the peptide via the processing of Ang I or Ang II. Since renin is typically secreted from the kidney and other tissues, the formation of Ang-(1-7) is likely to occur in the extracellular compartments including the blood, interstitial fluid, renal tubular fluid, and CSF. However, there is evidence for alternative renin isoforms in the kidney, brain, heart , and adrenal gland [15, 16, 17]. The renin isoform lacks the pre-pro domain of the protein that includes the secretory signal, thus the isoform should reside within the cell. Peters and colleagues originally reported that truncated renin localized to the mitochondria and that the renin isoform was internalized by the mitochondria [18, 19, 20, 21]. We recently reported the presence of active renin in a purified preparation of mitochondria from the sheep renal cortex, as well as evidence for mitochondrial Ang II and Ang-(1-7) [50–60 fmol/mg protein] . Moreover, the endopeptidases neprilysin and thimet oligopeptidase processed Ang I directly to Ang-(1-7) in mitochondria suggesting an Ang I-dependent pathway for the intracellular formation of Ang-(1-7) (see Neprilysin and Thimet Oligopeptidase sections). In renal NRK-52 epithelial cells, immunocytochemical staining for renin with the Inagami antibody was evident in the nucleus of these cells and active renin was confirmed by aliskerin-sensitive conversion of angiotensinogen to Ang I. Isolated nuclei also contained Ang I, Ang II, and Ang-(1-7) [5–20 fmol/mg protein]; however, the processing pathways within the nuclear compartment remain to be defined . Ishigami et al. reported a truncated renin transcript expressed in the proximal tubules of the mouse kidney . Targeted expression of this renin isoform within the proximal tubules was associated with a sustained elevation in blood pressure, but no change in the circulating levels of renin . Although the intracellular localization of the renin isoform or tubular content of angiotensins were not determined, overexpression of renin in tubules augmented blood pressure that suggests the primary intracellular generation of Ang II rather than Ang-(1-7). Indeed, Zhou and colleagues find that the intracellular expression of Ang II in the proximal tubules also resulted in a sustained increase in blood pressure  that is consistent with the demonstration of the intracellular AT1R and a local RAS within the kidney [25, 26, 27, 28].
Non-renin pathways for the processing of angiotensinogen to Ang I or Ang II include tonin, cathepsin G, and cathepsin A; however, the participation of these enzymes in the endogenous generation of angiotensins has yet to be firmly established . Moreover, it is not known whether there is a direct pathway for the formation of Ang-(1-7) from angiotensinogen and whether this contributes to the intracellular content of the peptide. Non-renin pathways for the formation of Ang-(1-7) (or Ang II) may also potentially occur through the processing of Ang-(1-12), a novel precursor peptide originally identified in rat urine by Nagata and colleagues . In this regard, neprilysin converts Ang-(1-12) to Ang-(1-7) in renal cortical membranes and by recombinant forms of both human and mouse neprilysin by a two-step process that involves Ang I as an intermediate product; however, the role of Ang-(1-12) in the generation of endogenous Ang-(1-7) in the circulation and tissues is presently unknown .
Neprilysin (EC 22.214.171.124; 95 kDa) is a metalloendopeptidase of the type II membrane-anchored family of enzymes . The peptidase was initially characterized in brain homogenates or membrane preparations to hydrolyze the opiate pentapeptide enkephalin which explained its original characterization as an “enkephalinase.” Inhibitors against neprilysin were originally developed to prolong the analgesic actions of the opiate peptides, although neprilysin was subsequently found to be expressed in a number of peripheral tissues . Cardiovascular interest in neprilysin initially reflected its ability to metabolize the family of natriuretic peptides including ANP, BNP, and uroguanylin. Moreover, McKinnie et al. report that neprilysin inactivates apelin, suggesting that beneficial cardiovascular effects of neprilysin inhibition may also reflect the protection of endogenous apelin . Neprilysin inhibitors were considered a potential therapeutic approach to prolong the natriuretic and vasorelaxant properties of these peptides; however, Ang II is also a substrate for neprilysin hydrolysis of the Tyr4-Ile5 bond to form Ang-(1-4) and combined inhibitors to neprilysin and ACE termed vasopeptidase inhibitors were developed to prevent the potential increase in circulating and renal Ang II by neprilysin inhibitors alone [34, 35, 36]. Although the vasopeptidase inhibitors were potent agents to lower blood pressure and reduce cardiac and renal damage, the first clinical agent omapatrilat was withdrawn due to a greater incidence of angioedema in patients. Subsequently, a new generation of agents have been developed that combine a neprilysin inhibitor and an AT1R antagonist to obviate the inhibitory effects on ACE, yet maintain blockade of the Ang II-AT1R axis. Indeed, the combined neprilysin/AT1R blockade may be a promising therapeutic approach for the treatment of heart failure .
Neprilysin is located on the vascular surface of blood vessels and is responsible for the direct conversion of Ang I to Ang-(1-7) in the circulation , particularly under conditions of chronic ACE inhibition (Fig. 1) . Neprilysin hydrolyzes the Pro7-Phe8 bond of Ang I to generate Ang-(1-7), as well as the Tyr4-Ile5 bond to form Ang-(1-4) that is consistent with the enzyme’s preference for aromatic and hydrophobic residues . The generation of circulating Ang-(1-7) from infused Ang I in ACE-blocked Wistar Kyoto (WKY) and spontaneously hypertensive rats (SHR) was abolished by the potent and selective neprilysin inhibitor SCH39370 . We further demonstrated that administration of another selective neprilysin inhibitor CGS24592 partially attenuated the blood pressure-lowering effects of the ACE inhibitor lisinopril in the SHR . The neprilysin inhibitor SCH39370 also reduced Ang-(1-7) levels in the rat hindlimb preparation perfused with Krebs buffer containing the ACE inhibitor lisinopril . Finally, Campbell and colleagues found that a dual ACE/neprilysin inhibitor lowered circulating levels of Ang-(1-7) in the SHR using a combined HPLC-RIA approach to quantify an array of angiotensins using an N-terminally directed antibody .
Thimet oligopeptidase (EC 126.96.36.199, 80 kDa) is a soluble metalloendopeptidase that resides within intracellular compartments of the cell. Similar to neprilysin, thimet oligopeptidase is an endopeptidase that prefers aromatic and hydrophobic residues and cleaves multiple peptide substrates . Thimet oligopeptidase hydrolyzes Ang I exclusively at the Pro7-Phe8 bond to form Ang-(1-7) (Fig. 1). In contrast to neprilysin, thimet oligopeptidase does not process Ang I to Ang-(1-4), although the peptidase does cleave Ang II to Ang-(1-4) (Fig. 1). The current data suggest that thimet oligopeptidase may be responsible for the intracellular processing of Ang I to Ang-(1-7). Pereira et al. find that thimet oligopeptidase was the primary activity in tissue homogenates of brain medulla that processed Ang I to Ang-(1-7) . Both neprilysin and thimet oligopeptidase contributed to the processing of Ang I to Ang-(1-7) within isolated mitochondria, and thimet oligopeptidase was the sole Ang-(1-7) forming activity in the 100,000 xg soluble fraction of renal mitochondria . In human proximal tubule HK-2 cells, cytosolic thimet oligopeptidase was the primary activity responsible for the generation of Ang-(1-7) from exogenous Ang I . Chronic treatment of the HK-2 cells with the cell-permeable metallopeptidase inhibitor JMV-390 reduced the intracellular levels of Ang-(1-7) which may reflect the inhibition of thimet oligopeptidase, although the JMV inhibitor may target other metallopeptidases or cell mechanisms that influence the intracellular expression of the peptide . Moreover, thimet oligopeptidase activity in isolated nuclei of NRK-52 renal epithelial cells processed Ang I exclusively to Ang-(1-7) and this peptidase may contribute to the nuclear levels of Ang-(1-7) within the cell . Suski et al. reported that Ang I was primarily converted to Ang-(1-7) in vascular smooth muscle cells (VSMC) as characterized by HPLC-MS analysis ; these data confirm our earlier study that thimet oligopeptidase directly processed Ang I to Ang-(1-7) in rat VSMC by HPLC characterization . Although the RAS was originally characterized as a classic endocrine or circulating system, there is compelling evidence for the intracellular expression of angiotensins and angiotensin receptors that include Ang-(1-7) and the MasR [9, 56, 57, 58, 59, 60, 61]. The mechanisms for intracellular expression of Ang-(1-7) are currently unknown; however, thimet oligopeptidase should be considered as one candidate processing enzyme in the cellular Ang-(1-7) axis.
Prolyl oligopeptidase (EC 188.8.131.52, 75 kDa), also known as prolyl endopeptidase (PEP), is a soluble intracellular serine peptidase that cleaves the Pro7-Phe8 bond of both Ang I and Ang II to form Ang-(1-7). Thus, prolyl oligopeptidase may function as both an endopeptidase and a monocarboxypeptidase in the processing of angiotensins, as well as the hydrolysis of other peptides that contain a Pro-XX motif including TRH, substance P, oxytocin, bradykinin and vasopressin . Although prolyl oligopeptidase is considered a cytosolic peptidase, membrane and nuclear forms of the enzyme have been described in both central and peripheral cells suggesting a role for the enzyme in the intracellular expression of peptides . Santos et al. report that prolyl oligopeptidase activity was involved in the extracellular conversion of Ang I to Ang-(1-7) in human aortic endothelial cells, although it remains unclear as to whether the peptidase was secreted into the media or that the peptidase resides on the plasma membrane of endothelial cells . Domenig et al. found that although neprilysin was the predominant Ang-(1-7) forming activity in the kidney, prolyl oligopeptidase activity contributed approximately 20% and 10% to Ang-(1-7) in the mouse and human kidney, respectively, based on the inhibition by Z-prolyl prolinal (ZPP) . Prolyl oligopeptidase would appear to be an ideal enzymatic candidate for the processing of both Ang I and Ang II to Ang-(1-7); however, treatment approaches with more selective inhibitors against the peptidase have generally revealed beneficial effects that contrast with the expected actions of Ang-(1-7), particularly regarding inflammation [62, 64, 65].
Angiotensin-Converting Enzyme 2
ACE2 is a membrane-bound monocarboxypeptidase (EC 184.108.40.206; 90-120 kDa) that converts Ang II directly to Ang-(1-7) (Fig. 1). ACE2 was initially characterized as an ACE homolog (~40% homology) that cleaved Ang I to the nonapeptide Ang-(1-9), but not directly to Ang II . Subsequent studies found that Ang II exhibits far better kinetic values as a substrate for human ACE2 that would favor processing of Ang II over that of Ang I . Among a number of peptide substrates (> 100) that were screened for human ACE2, Vickers et al. reported that only apelin 13 exhibited comparable kinetic values to that of Ang II . In the murine heart, Ang II was primarily converted to Ang-(1-7) by ACE2 and that in the presence of the ACE2 inhibitor MLN-4760 or in ACE2 null mice there was little metabolism of Ang II . In contrast, under identical kinetic conditions, Ang I was primarily converted to Ang-(1-9) by carboxypeptidase A and not ACE2 in both the wild-type and ACE2 knockout mice .
In regard to the benefits of an activated ACE2 pathway, several compounds have been identified that may act as allosteric activators of ACE2 including xanthenone (XNT) and diminazene aceturate (DIZE) to promote a higher ratio of Ang-(1-7) to Ang II (89) . Chronic treatment with DIZE ameliorated the extent of pulmonary hypertension and fibrosis, renal tissue injury, and myocardial infarction consistent with enhanced levels of Ang-(1-7) and a reduction in Ang II [90, 91, 92, 93]. Interestingly, DIZE treatment was also associated with increased mRNA levels of ACE2 suggesting that DIZE may exhibit actions apart from the direct activation of the peptidase. However, the stimulatory effects of DIZE on either ACE2 activity or expression have not been confirmed by others. Haber et al. found no effect of DIZE on soluble ACE2 activity or an influence on Ang II-dependent hypertension using similar doses of DIZE as previously reported . Velkosa et al. also show no direct effect of various concentrations of DIZE on renal ACE2 activity ex vivo, as well as no in vivo effect on cardiac ACE2 activity or Ang-(1-7) content in the 5/6 nephrectomized rat following a 2-week administration of DIZE . Indeed, this study reported that DIZE normalized the marked increase in cardiac ACE activity and Ang II suggesting that ACE may be a more relevant target than ACE2 to impact the cardiac RAS . DIZE also failed to increase ACE2 activity or enhance the local vascular actions of Ang-(1-7) in a preparation of isolated pig coronary arteries .
Conceptually, the use of ACE2 as a therapeutic agent to chronically alter the balance of Ang II and Ang-(1-7) is challenging. ACE activity in the circulation and the vasculature surface is significant with a very high capacity to generate Ang II. This reflects not simply the abundance of ACE but the marked capability of angiotensinogen and renin to generate the ACE substrate Ang I. Moreover, reduced Ang II levels by exogenous ACE2 should stimulate the generation of Ang II that reflects inactivation of negative feedback mechanisms on renin. Therefore, it is difficult to conceive that sufficiently high levels of ACE2 can be achieved to chronically reduce Ang II and increase Ang-(1-7) except with the possible addition of an ACE inhibitor. In this case, supplementation of ACE2 may degrade residual levels of Ang II and the circulating levels of Ang-(1-7) may be augmented, particularly as the Ang-(1-7)-degrading pathway in the circulation is attenuated by the ACE inhibitor. In this regard, it is worth noting that Jin and colleagues have recently developed a Fc fusion protein to ACE2 that markedly prolongs the activity of the enzyme by reducing its clearance; however, the ACE2-fusion protein was assessed in an Ang II-infusion model that has suppressed endogenous Ang II, and other models of hypertension need to be examined .
It is presently unclear how increased circulating ACE2 augments Ang-(1-7) tissue levels as the intracellular mechanisms for Ang-(1-7) generation are not known. One possibility is that administered ACE2 increases circulating levels of Ang-(1-7) and the peptide is subsequently internalized by the MasR into a stable or protected intracellular compartment. Indeed, Gironacci and colleagues describe internalization of the Mas receptor following stimulation by Ang-(1-7); however, the assessment of intracellular Ang-(1-7) was not determined . Alternatively, ACE2 treatment may alter that intracellular signaling milieu to attenuate oxidative stress or inflammation that impacts the local generation of Ang II and Ang-(1-7). Similar to neprilysin and ACE, ACE2 is primarily expressed as an ectocellular membrane-anchored peptidase that should readily access circulating or interstitial levels of Ang II. We observed that isolated nuclei from sheep renal cortex expressed ACE2 activity that converted Ang II to Ang-(1-7) and that the ACE2 inhibitor MLN4760 increased the oxidative stress response to Ang II suggesting that intracellular ACE2 may regulate the cellular balance of Ang II and Ang-(1-7) . Tikellis et al. show that the renal content of Ang-(1-7) was reduced in ACE2-/- mice to a similar extent as that following chronic treatment with the potent ACE inhibitor perindopril . Lavrentyev and colleagues also found that siRNA treatment against ACE2 reduced cellular levels of Ang-(1-7) in rat aortic smooth muscle cells . Finally, Mompeon et al. recently demonstrate that estradiol increased the cellular levels of Ang-(1-7) that was associated with higher levels of both ACE and ACE2 by activation of the ERα subtype in human umbilical vein endothelial cells . Overall, these studies suggest that intracellular expression of Ang-(1-7) is dependent in part on the processing of Ang II by ACE2 either intracellularly or extracellular conversion with the subsequent uptake of Ang-(1-7) by the Mas receptor.
Prolyl carboxypeptidase is a monocarboxypeptidase [EC 220.127.116.11, Angiotensinase C, 58 kDa] with specificity for the C-terminal hydrolysis of the Pro-X bond where X is a hydrophobic residue . The enzyme is capable of converting Ang II to Ang-(1-7), as well as degrading α-MSH, but activating the pre-kallikrein protease. In contrast to prolyl oligopeptidase and ACE2, the pH optima for prolyl carboxypeptidase is in the more acidic range of pH 4-5. Indeed, Grobe et al. find that prolyl carboxypeptidase was responsible for Ang II to Ang-(1-7) conversion in mouse renal cortex and urine at pH < 6.0 while ACE2 was predominant at pH >7.0 . Velez et al. report that the mixed prolyl oligopeptidase/prolyl carboxypeptidase inhibitor ZPP partially blocked Ang II to Ang-(1-7) conversion, but had no effect on Ang I metabolism and concluded that the Ang-(1-7) forming enzymes from Ang II in human glomerular endothelial cells were prolyl carboxypeptidase and ACE2 . Xu et al. find increased plasma levels of prolyl carboxypeptidase by ELISA in a cohort of obese diabetic patients; however, the circulating levels of Ang II or Ang-(1-7) were not evaluated in this study . Interestingly, prolyl carboxypeptidase knockout mice exhibit higher blood pressure, increased oxidative stress, reduced vascular eNOS expression, renal damage, and cardiac dysfunction; however, neither circulating nor cardiac levels of Ang II and Ang-(1-7) were altered in this transgenic mouse as compared to wild-type [105, 106]. Finally, Jeong et al. report the prolyl carboxypeptidase knockout mice were protected against the metabolic effects of diet-induced obesity which runs counter to the expected effects of a higher Ang II: Ang-(1-7) ratio and suggest non-RAS targets of prolyl carboxypeptidase .
Angiotensin-(1-7) Degrading Pathways
The predominant pathway of the classical RAS for the conversion of Ang I to the bioactive peptide Ang II is catalyzed by the metallopeptidase ACE [EC 18.104.22.168], a dipeptidyl carboxypeptidase that cleaves two residues from the carboxy terminus of Ang I (Fig. 1) . The peptidase is a membrane-bound, glycosylated protein (120–180 kDa) that is expressed in multiple tissues . Soluble forms of the enzyme are present in the circulation, CSF, lymph fluid, and urine that retain peptidase activity . The soluble form of ACE arises from the hydrolysis of the membrane-anchoring or stalk region of the protein that may reflect the processing by A Disintegrin and Metalloproteinase (ADAM) family of metallo-enzymes, although the precise role of ACE shedding in cardiovascular disease is presently unclear. Somatic ACE is characterized by two active sites termed N and C terminal domains that likely arose from the gene duplication of germinal or testicular ACE that contains only the single C terminal active site. In addition to forming Ang II, ACE degrades a number of other peptides that exhibit cardiovascular actions including bradykinin, substance P, and acetyl-SDKP . Indeed, the cardioprotective effects of ACE inhibitors may reflect the protection of these peptides from metabolism, as well as the inhibitory effects on Ang II generation. In lieu of the increased circulating levels of Ang-(1-7) to ACE inhibitors, we postulated that Ang-(1-7) may be an endogenous substrate for ACE and demonstrated that ACE hydrolyzes Ang-(1-7) at the Ile5-His6 bond to yield the pentapeptide Ang-(1-5) and the dipeptide His-Pro (Fig. 1) . Treatment with the potent ACE inhibitor lisinopril markedly reduced the clearance of the peptide and addition of the ACE inhibitor was required to demonstrate the accumulation of Ang-(1-7) derived from either Ang II or Ang I in isolated proximal tubules and following infusion of Ang I in SHR and WKY [44, 110]. Thus, the reduced metabolism of Ang-(1-7) likely contributes to the elevation in circulating levels of Ang-(1-7) following the chronic treatment with ACE inhibitors in experimental animals and in humans. These data suggest a pivotal role for ACE to regulate the balance of Ang II and Ang-(1-7) tone as the two peptides exhibit strikingly different actions from one another.
Dipeptidyl Peptidase 3
DPP 3 belongs to a family of metallo-aminopeptidases that sequentially cleave 2 residues from the N-terminus of peptides ≤8 residues in length that explains our previous results that Ang I, apelin-13 and neurotensin were not substrates for the Ang-(1-7)-degrading activity in the CSF and brain . We obtained a human recombinant form of DPP 3 that hydrolyzed Ang-(1-7) in two steps . DPP 3 initially cleaved Ang-(1-7) at the Arg2-Val3 bond to form Ang-(3-7) and the dipeptide Arg1-Asp2. Ang-(3-7) is then very rapidly cut at Tyr4-Ile5 to form Ang-(5-7) and Val3-Tyr4. The kinetic analysis of DPP 3 hydrolysis revealed a higher efficiency constant [kcat/Km] for Ang-(3-7) than Ang-(1-7) . The preferred hydrolysis of Ang-(3-7) by DPP 3 explains the inability to demonstrate the accumulation of Ang-(3-7) following the initial metabolism of Ang-(1-7). In regard to an in vivo role for DPP 3 to modulate Ang-(1-7), human HK-2 cells were treated with varying doses of the JMV-390 inhibitor and we assessed both the endogenous content of Ang-(1-7) and the intracellular DPP-3/Ang-(1-7) degrading activity in the cells. Treatment with 20 nM and 200 nM JMV-390 reduced DPP3 activity by >30% and > 80%, respectively, as compared to control suggesting that the inhibitor effectively penetrates the cells . The lower dose of JMV increased the cellular content Ang-(1-7) approximately two-fold, although this did not reach statistical significance. The higher dose of JMV, however, significantly reduced the intracellular levels of the peptide . The higher JMV dose may block other peptidases including thimet oligopeptidase that may be involved in the intracellular generation of Ang-(1-7) in the renal cells . Thus, the blockade of Ang-(1-7)-forming enzymes by the high-dose JMV may override any protective effects of DPP 3 inhibition.
Both Ang II and Ang-(1-7) share the same N-terminal sequence and are likely substrates for N-terminal directed metabolism. Aminopeptidase A [EC 22.214.171.124, 50 kDa] was characterized as a classic angiotensinase that hydrolyzed the Asp1-Arg2 bond to Ang II to form Ang-(2-8) or Ang III . Grobe and colleagues applied “in situ” MALDI to characterize both renal and cardiac metabolism of exogenous Ang II and Ang-(1-7) [115, 116]. Ang-(1-7) was the primary product from Ang II in the renal cortex while Ang III was the major metabolite in the medulla . In the heart, Ang III and Ang-(1-7) were products of Ang II metabolism catalyzed by Aminopeptidase A and ACE2, respectively . These data confirm earlier HPLC-based studies on the contribution of ACE2 to Ang-(1-7) formation in the mouse and human heart [68, 117]. In mouse podocytes, Aminopeptidase A contributed to the metabolism of Ang-(1-7) to Ang-(2-7) and the subsequent conversion to Ang-(3-7) by arginine aminopeptidase (EC 126.96.36.199) – an identical pathway for the metabolism of Ang II to Ang III and Ang-(3-8) [46, 114]. Aminopeptidase A is widely distributed in tissues predominantly in a membrane-bound form, although soluble forms are present in the circulation, urine, and CSF . Aminopeptidase A knockout mice show an increase in blood pressure, an enhanced pressor response to Ang II and greater susceptibility to glomeruli injury that would be consistent with a role of the peptidase in the metabolism of Ang II; however, it is not known the extent that circulating endogenous levels of Ang-(1-7) are altered to potentially mitigate against the cardiovascular effects of higher Ang II [118, 119].
Accumulating evidence from multiple laboratories clearly indicates that activation of the Ang-(1-7)-AT7/MasR axis appears to be a potentially important therapeutic target in the treatment of cardiovascular disease and other pathologies . In lieu of the described peptidases that degrade Ang-(1-7) and the apparent reliance on Ang II as an endogenous substrate for the generation of the peptide in several tissues, the development of selective non-peptide analogs of Ang-(1-7) that target both the Mas receptor and the newly described Mas-related receptor D (MRG-D)  may be of particular benefit in terms of their oral availability, greater resistance to peptidase metabolism, improved selectivity, their potential ability to accumulate within the cell and to cross the blood-brain barrier.
A functional intracellular AT7/MasR was first identified on isolated nuclei from the ovine kidney that was linked to NO generation following exposure to low pM doses of Ang-(1-7) . These findings were recently corroborated in the brain that revealed evidence of the MasR on nuclei and mitochondria, as well as Ang-(1-7)-dependent stimulation of NO . Moreover, AT7/MasR binding on renal nuclei and the Ang-(1-7)-evoked NO response were attenuated in aged sheep and in adult sheep exposed to betamethasone in utero as compared to the younger non-exposed animals [9, 99]. Conversely, intracellular levels of the AT1R that were associated with stimulation of oxidative stress on isolated nuclei were increased in the older animals and in the betamethasone-exposed sheep [9, 98]. Abadir et al. originally reported an increased ratio of AT1R: AT2R receptors in isolated renal mitochondrial of aging mice . Valenzuela et al. also find reduced an increased AT1R:AT2R ratio in brain mitochondria of aging mice that may lead to higher cellular levels of oxidative stress [128, 129]. Overall, these novel findings of nuclear and mitochondrial angiotensin receptors support extensive evidence for an intracellular RAS within various tissues although the exact role of an activated intracellular RAS to influence cardiovascular disease and other pathologies is not resolved and requires further study. Nevertheless, peptidase-resistant and cell-permeable agonists of the Ang-(1-7) axis may provide additional cardioprotective effects to conventional approaches to block the RAS and may expand the targeted therapies required to combat cardiovascular disease.
I am most fortunate to have shared a moment in time with a number of very talented graduate students and postdoctoral fellows including Karl Pendergrass, Liliya Yamaleyeva, Hossam Shaltout, TanYa Gwathmey, Sarah Lindsey, Jonathan Cohen, Shea Gilliam, Allyson Marshall, Ebaa Al-Zayadneh, Bryan Wilson, and Nildris Cruz-Diaz, as well as Brian Westwood and Nancy Pirro whose research efforts to the studies in this review I gratefully acknowledge. Portions of this work were supported by grants from the National Institute of Health grants (HL-56973, HL-51952, HD-084227, HD-047584, HL-091797, HL-146818, GM102773 and HD-017644) and the American Heart Association (AHA-151521, AHA-355741 and AHA-18TPA34170522). An unrestricted grant from the Farley-Hudson Foundation (Jacksonville, NC), Groskert Heart Fund, and the Wake Forest Venture Fund is also acknowledged.
- 1.Hernandez Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, et al. Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension (Dallas, TX: 1979). 2008;51(5):1312–7. https://doi.org/10.1161/hypertensionaha.107.108944.CrossRefGoogle Scholar
- 9.Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1-7)-MAS receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol. 2014;4:201. https://doi.org/10.3389/fendo.2013.00201.CrossRefGoogle Scholar
- 12.Gonzalez AA, Lara LS, Luffman C, Seth DM, Prieto MC. Soluble form of the (pro)renin receptor is augmented in the collecting duct and urine of chronic angiotensin II-dependent hypertensive rats. Hypertension (Dallas, TX: 1979). 2011;57(4):859–64. https://doi.org/10.1161/hypertensionaha.110.167957.CrossRefGoogle Scholar
- 13.Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension (Dallas, TX: 1979). 2011;57(3):355–62. https://doi.org/10.1161/hypertensionaha.110.163519.CrossRefGoogle Scholar
- 14.Gonzalez AA, Liu L, Lara LS, Seth DM, Navar LG, Prieto MC. Angiotensin II stimulates renin in inner medullary collecting duct cells via protein kinase C and independent of epithelial sodium channel and mineralocorticoid receptor activity. Hypertension (Dallas, TX: 1979). 2011;57(3):594–9. https://doi.org/10.1161/hypertensionaha.110.165902.CrossRefGoogle Scholar
- 16.Lavoie JL, Liu X, Bianco RA, Beltz TG, Johnson AK, Sigmund CD. Evidence supporting a functional role for intracellular renin in the brain. Hypertension (Dallas, TX: 1979). 2006;47(3):461–6. https://doi.org/10.1161/01.HYP.0000203308.52919.dc.CrossRefGoogle Scholar
- 17.Ishigami T, Kino T, Chen L, Minegishi S, Araki N, Umemura M, et al. Identification of bona fide alternative renin transcripts expressed along cortical tubules and potential roles in promoting insulin resistance in vivo without significant plasma renin activity elevation. Hypertension (Dallas, TX: 1979). 2014;64(1):125–33. https://doi.org/10.1161/hypertensionaha.114.03394.CrossRefGoogle Scholar
- 18.Peters J, Wanka H, Peters B, Hoffmann S. A renin transcript lacking exon 1 encodes for a non-secretory intracellular renin that increases aldosterone production in transgenic rats. J Cell Mol Med. 2008;12(4):1229–37. https://doi.org/10.1111/j.1582-4934.2008.00132.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Li XC, Cook JL, Rubera I, Tauc M, Zhang F, Zhuo JL. Intrarenal transfer of an intracellular fluorescent fusion of angiotensin II selectively in proximal tubules increases blood pressure in rats and mice. Am J Physiol Renal Physiol. 2011;300(5):F1076–88. https://doi.org/10.1152/ajprenal.00329.2010.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Li XC, Zhuo JL. Proximal tubule-dominant transfer of AT(1a) receptors induces blood pressure responses to intracellular angiotensin II in AT(1a) receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol. 2013;304(8):R588–98. https://doi.org/10.1152/ajpregu.00338.2012.CrossRefPubMedPubMedCentralGoogle Scholar
- 28.Davisson RL, Ding Y, Stec DE, Catterall JF, Sigmund CD. Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. Physiol Genomics. 1999;1(1):3–9. https://doi.org/10.1152/physiolgenomics.19188.8.131.52.CrossRefPubMedGoogle Scholar
- 42.Campbell DJ, Anastasopoulos F, Duncan AM, James GM, Kladis A, Briscoe TA. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther. 1998;287(2):567–77.PubMedGoogle Scholar
- 44.Shaltout HA, Westwood BM, Averill DB, Ferrario CM, Figueroa JP, Diz DI, et al. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol. 2007;292(1):F82–91. https://doi.org/10.1152/ajprenal.00139.2006.CrossRefPubMedGoogle Scholar
- 48.Velez JC, Ryan KJ, Harbeson CE, Bland AM, Budisavljevic MN, Arthur JM, et al. Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli. Hypertension (Dallas, TX: 1979). 2009;53(5):790–7. https://doi.org/10.1161/hypertensionaha.109.128819.CrossRefGoogle Scholar
- 49.Modrall JG, Sadjadi J, Brosnihan KB, Gallagher PE, Yu CH, Kramer GL, et al. Depletion of tissue angiotensin-converting enzyme differentially influences the intrarenal and urinary expression of angiotensin peptides. Hypertension (Dallas, TX: 1979). 2004;43(4):849–53. https://doi.org/10.1161/01.HYP.0000121462.27393.f6.CrossRefGoogle Scholar
- 51.Pereira MG, Souza LL, Becari C, Duarte DA, Camacho FR, Oliveira JA, et al. Angiotensin II-independent angiotensin-(1-7) formation in rat hippocampus: involvement of thimet oligopeptidase. Hypertension (Dallas, TX: 1979). 2013;62(5):879–85. https://doi.org/10.1161/hypertensionaha.113.01613.CrossRefGoogle Scholar
- 52.Wilson BA, Cruz-Diaz N, Marshall AC, Pirro NT, Su Y, Gwathmey TM, et al. An angiotensin-(1-7) peptidase in the kidney cortex, proximal tubules, and human HK-2 epithelial cells that is distinct from insulin-degrading enzyme. Am J Physiol Renal Physiol. 2015;308(6):F594–601. https://doi.org/10.1152/ajprenal.00609.2014.CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Cruz-Diaz N, Wilson BA, Pirro NT, Brosnihan KB, Marshall AC, Chappell MC. Identification of dipeptidyl peptidase 3 as the angiotensin-(1-7) degrading peptidase in human HK-2 renal epithelial cells. Peptides. 2016;83:29–37. https://doi.org/10.1016/j.peptides.2016.06.005.CrossRefPubMedPubMedCentralGoogle Scholar
- 54.Suski M, Gebska A, Olszanecki R, Stachowicz A, Uracz D, Madej J, et al. Influence of atorvastatin on angiotensin I metabolism in resting and TNF-alpha-activated rat vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst: JRAAS. 2014;15(4):378–83. https://doi.org/10.1177/1470320313475907.CrossRefPubMedGoogle Scholar
- 55.Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4. 24.15) in vascular smooth muscle cells. J Vasc Med Biol. 1994;5:129–37.Google Scholar
- 56.Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension (Dallas, TX: 1979). 2007;50(4):596–9. https://doi.org/10.1161/hypertensionaha.106.076216.CrossRefGoogle Scholar
- 62.Myohanen TT, Garcia-Horsman JA, Tenorio-Laranga J, Mannisto PT. Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity. J Histochem Cytochem: Off J Histochem Soc. 2009;57(9):831–48. https://doi.org/10.1369/jhc.2009.953711.CrossRefGoogle Scholar
- 63.Santos RA, Brosnihan KB, Jacobsen DW, DiCorleto PE, Ferrario CM. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension (Dallas, TX: 1979). 1992;19(2 Suppl):Ii56–61.Google Scholar
- 68.Garabelli PJ, Modrall JG, Penninger JM, Ferrario CM, Chappell MC. Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol. 2008;93(5):613–21. https://doi.org/10.1113/expphysiol.2007.040246.CrossRefPubMedPubMedCentralGoogle Scholar
- 69.Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension (Dallas, TX: 1979). 2006;48(5):914–20. https://doi.org/10.1161/01.hyp.0000244543.91937.79.CrossRefGoogle Scholar
- 70.Yamaleyeva LM, Gilliam-Davis S, Almeida I, Brosnihan KB, Lindsey SH, Chappell MC. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2.Lewis rats with early-onset diabetes. Am J Physiol Renal Physiol. 2012;302(11):F1374–84. https://doi.org/10.1152/ajprenal.00656.2011.CrossRefPubMedPubMedCentralGoogle Scholar
- 71.Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail. 2009;15(7):565–71. https://doi.org/10.1016/j.cardfail.2009.01.014.CrossRefPubMedPubMedCentralGoogle Scholar
- 75.Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol. 2006;168(6):1808–20. https://doi.org/10.2353/ajpath.2006.051091.CrossRefPubMedPubMedCentralGoogle Scholar
- 80.Zhong J, Basu R, Guo D, Chow FL, Byrns S, Schuster M et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation. 2010;122(7):717-728, 18 p following 28. doi: https://doi.org/10.1161/circulationaha.110.955369.CrossRefGoogle Scholar
- 81.Wysocki J, Ye M, Rodriguez E, Gonzalez-Pacheco FR, Barrios C, Evora K, et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension (Dallas, TX: 1979). 2010;55(1):90–8. https://doi.org/10.1161/hypertensionaha.109.138420.CrossRefGoogle Scholar
- 82.Ye M, Wysocki J, Gonzalez-Pacheco FR, Salem M, Evora K, Garcia-Halpin L, et al. Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension (Dallas, TX: 1979). 2012;60(3):730–40. https://doi.org/10.1161/hypertensionaha.112.198622.CrossRefGoogle Scholar
- 83.Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90(5):783–90. https://doi.org/10.1113/expphysiol.2005.031096.CrossRefPubMedGoogle Scholar
- 84.Diez-Freire C, Vazquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27(1):12–9. https://doi.org/10.1152/physiolgenomics.00312.2005.CrossRefPubMedGoogle Scholar
- 85.Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Diez-Freire C, Dooies A, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2010;182(8):1065–72. https://doi.org/10.1164/rccm.200912-1840OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 86.Yamazato M, Yamazato Y, Sun C, Diez-Freire C, Raizada MK. Overexpression of angiotensin-converting enzyme 2 in the rostral ventrolateral medulla causes long-term decrease in blood pressure in the spontaneously hypertensive rats. Hypertension (Dallas, TX: 1979). 2007;49(4):926–31. https://doi.org/10.1161/01.hyp.0000259942.38108.20.CrossRefGoogle Scholar
- 88.Wysocki J, Ye M, Khattab AM, Fogo A, Martin A, David NV, et al. Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy. Kidney Int. 2017;91(6):1336–46. https://doi.org/10.1016/j.kint.2016.09.032.CrossRefPubMedGoogle Scholar
- 90.Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M, et al. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension (Dallas, TX: 1979). 2013;62(4):746–52. https://doi.org/10.1161/hypertensionaha.113.01337.CrossRefGoogle Scholar
- 93.Shenoy V, Gjymishka A, Jarajapu YP, Qi Y, Afzal A, Rigatto K, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187(6):648–57. https://doi.org/10.1164/rccm.201205-0880OC.CrossRefPubMedPubMedCentralGoogle Scholar
- 94.Haber PK, Ye M, Wysocki J, Maier C, Haque SK, Batlle D. Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro. Hypertension (Dallas, TX: 1979). 2014;63(4):774–82. https://doi.org/10.1161/hypertensionaha.113.02856.CrossRefGoogle Scholar
- 96.Raffai G, Khang G, Vanhoutte PM. Angiotensin-(1-7) augments endothelium-dependent relaxations of porcine coronary arteries to bradykinin by inhibiting angiotensin-converting enzyme 1. J Cardiovasc Pharmacol. 2014;63(5):453–60. https://doi.org/10.1097/fjc.0000000000000069.CrossRefPubMedGoogle Scholar
- 97.Liu P, Wysocki J, Souma T, Ye M, Ramirez V, Zhou B, et al. Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney Int. 2018; https://doi.org/10.1016/j.kint.2018.01.029.CrossRefGoogle Scholar
- 98.Cerniello FM, Carretero OA, Longo Carbajosa NA, Cerrato BD, Santos RA, Grecco HE, et al. MAS1 receptor trafficking involves ERK1/2 activation through a beta-arrestin2-dependent pathway. Hypertension (Dallas, TX: 1979). 2017;70(5):982–9. https://doi.org/10.1161/hypertensionaha.117.09789.CrossRefGoogle Scholar
- 99.Gwathmey TM, Shaltout HA, Rose JC, Diz DI, Chappell MC. Glucocorticoid-induced fetal programming alters the functional complement of angiotensin receptor subtypes within the kidney. Hypertension (Dallas, TX: 1979). 2011;57(3):620–6. https://doi.org/10.1161/hypertensionaha.110.164970.CrossRefGoogle Scholar
- 101.Mompeon A, Lazaro-Franco M, Bueno-Beti C, Perez-Cremades D, Vidal-Gomez X, Monsalve E, et al. Estradiol, acting through ER alpha, induces endothelial non-classic renin-angiotensin system increasing angiotensin 1-7 production. Mol Cell Endocrinol. 2016;422:1–8. https://doi.org/10.1016/j.mce.2015.11.004.CrossRefPubMedGoogle Scholar
- 102.Tan F, Erdos EG. Lysosomal Pro-X carboxypeptidase. In: Barrett A, Woessner J, Rawlings N, editors. Handbook of proteolytic enzymes. 2nd ed. London: Elsevier Academic Press; 2004. p. 1936–8.Google Scholar
- 103.Grobe N, Weir NM, Leiva O, Ong FS, Bernstein KE, Schmaier AH, et al. Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol. 2013;304(10):C945–53. https://doi.org/10.1152/ajpcell.00346.2012.CrossRefPubMedPubMedCentralGoogle Scholar
- 105.Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, et al. Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood. 2011;117(14):3929–37. https://doi.org/10.1182/blood-2010-11-318527.CrossRefPubMedPubMedCentralGoogle Scholar
- 106.Maier C, Schadock I, Haber PK, Wysocki J, Ye M, Kanwar Y, et al. Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. J Mol Med (Berlin, Germany). 2017;95(5):473–86. https://doi.org/10.1007/s00109-017-1513-9.CrossRefGoogle Scholar
- 108.Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonzalez-Villalobos RA, et al. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev. 2013;65(1):1–46. https://doi.org/10.1124/pr.112.006809.CrossRefPubMedPubMedCentralGoogle Scholar
- 111.Marshall AC, Shaltout HA, Pirro NT, Rose JC, Diz DI, Chappell MC. Antenatal betamethasone exposure is associated with lower ANG-(1-7) and increased ACE in the CSF of adult sheep. Am J Physiol Regul Integr Comp Physiol. 2013;305(7):R679–88. https://doi.org/10.1152/ajpregu.00321.2013.CrossRefPubMedPubMedCentralGoogle Scholar
- 117.Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation. 2003;108(14):1707–12. https://doi.org/10.1161/01.cir.0000094734.67990.99.CrossRefPubMedGoogle Scholar
- 120.Chappell MC, Al Zayadneh EM. Angiotensin-(1-7) and the regulation of anti-fibrotic signaling pathways. J Cell Signal. 2017;2(1):1–3.Google Scholar
- 126.Costa-Besada MA, Valenzuela R, Garrido-Gil P, Villar-Cheda B, Parga JA, Lanciego JL, Labandeira-Garcia JL. Paracrine and intracrine angiotensin 1-7/Mas receptor axis in the substantia nigra of rodents, monkeys, and humans. Mol Neurobiol. 2017; https://doi.org/10.1007/s12035-017-0805-y. [Epub ahead of print].CrossRefGoogle Scholar
- 128.Valenzuela R, Costa-Besada MA, Iglesias-Gonzalez J, Perez-Costas E, Villar-Cheda B, Garrido-Gil P, et al. Mitochondrial angiotensin receptors in dopaminergic neurons. Role in cell protection and aging-related vulnerability to neurodegeneration. Cell Death Dis. 2016;7(10):e2427. https://doi.org/10.1038/cddis.2016.327.CrossRefPubMedPubMedCentralGoogle Scholar
- 129.Villar-Cheda B, Costa-Besada MA, Valenzuela R, Perez-Costas E, Melendez-Ferro M, Labandeira-Garcia JL. The intracellular angiotensin system buffers deleterious effects of the extracellular paracrine system. Cell Death Dis. 2017;8(9):e3044. https://doi.org/10.1038/cddis.2017.439.CrossRefPubMedPubMedCentralGoogle Scholar